Evidence map›Paper›PMID 38608170›Full record

ArticleHuman vaccines & immunotherapeutics2024

Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six-group B streptococcus polysaccharides.

Kirsty Le Doare, Michelle A Gaylord, Annaliesa S Anderson, Nick Andrews, Carol J Baker, Shanna Bolcen, Arif Felek, Peter C Giardina, Christopher D Grube, Tom Hall and 16 more

Open access · goldAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 6 countries.

Kirsty Le DoareCentre for Neonatal and Paediatric Infection, Institute for Infection and Immunity, St George's, University of London, London, UK.
Michelle A GaylordPfizer Vaccine Research & Development, Pearl River, NY, USA.
Annaliesa S AndersonPfizer Vaccine Research & Development, Pearl River, NY, USA.
Nick AndrewsImmunisation and Vaccine Preventable Diseases Division, United Kingdom Health Security Agency (UKHSA), London, UK.
Carol J BakerDepartment of Pediatrics, Division of Infectious Disease, McGovern Medical School and UT Health, Houston, TX, USA.
Shanna BolcenThe Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Arif FelekVaccine Division, Scientific Research & Innovation Group, MHRA, Potters Bar, UK.
Peter C GiardinaPfizer Vaccine Research & Development, Pearl River, NY, USA.
Christopher D GrubePfizer Vaccine Research & Development, Pearl River, NY, USA.
Tom HallCentre for Neonatal and Paediatric Infection, Institute for Infection and Immunity, St George's, University of London, London, UK.ORCID 0000-0002-9001-6684
Bassam HallisUK Health Security Agency, Porton Down, UK.
Alane IzuSouth African Medical Research Council: Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Shabir A MadhiSouth African Medical Research Council: Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Pete ManiatisThe Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Mary MathesonUK Health Security Agency, Porton Down, UK.
Fatme MawasVaccine Division, Scientific Research & Innovation Group, MHRA, Potters Bar, UK.
Andrew McKeenPfizer Global Biometrics & Data Management, Pearl River, NY, USA.
Julia RhodesThe Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Bailey AlstonEagle Global Scientific, Atlanta, GA, USA.
Palak PatelThe Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Stephanie SchragThe Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Raphael SimonPfizer Vaccine Research & Development, Pearl River, NY, USA.
Charles Y TanPfizer Global Biometrics & Data Management, Pearl River, NY, USA.
Stephen TaylorUK Health Security Agency, Porton Down, UK.
Gaurav KwatraSouth African Medical Research Council: Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Andrew GorringeUK Health Security Agency, Porton Down, UK.
Pfizer (United States) · USCenters for Disease Control and Prevention · USUK Health Security Agency · GBSouth African Medical Research Council · ZASt George's, University of London · GBEagle Industry (Japan) · JPThe University of Texas Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measurement of IgG antibodies against group B streptococcus (GBS) capsular polysaccharide (CPS) by use of a standardized and internationally accepted multiplex immunoassay is important for the evaluation of candidate maternal GBS vaccines in order to compare results across studies. A standardized assay is also required if serocorrelates of protection against invasive GBS disease are to be established in infant sera for the six predominant GBS serotypes since it would permit the comparison of results across the six serotypes. We undertook an interlaboratory study across five laboratories that used standardized assay reagents and protocols with a panel of 44 human sera to measure IgG antibodies against GBS CPS serotypes Ia, Ib, II, III, IV, and V. The within-laboratory intermediate precision, which included factors like the lot of coated beads, laboratory analyst, and day, was generally below 20% relative standard deviation (RSD) for all six serotypes, across all five laboratories. The cross-laboratory reproducibility was < 25% RSD for all six serotypes, which demonstrated the consistency of results across the different laboratories. Additionally, anti-CPS IgG concentrations for the 44-member human serum panel were established. The results of this study showed assay robustness and that the resultant anti-CPS IgG concentrations were reproducible across laboratories for the six GBS CPS serotypes when the standardized assay was used.

Indexed as

Guillain-Barre SyndromeImmunoglobulin GHumansImmunoassayInfantPolysaccharidesReproducibility of ResultsStreptococcus agalactiaeImmunoglobulin GPolysaccharidescorrelate of protectionGroup B streptococcusmaternalneonatalvaccines

Identifiers

PMID38608170
PMCPMC11018077
OpenAlexW4394769937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.